ArticleTargeted oncology2022

Changes in Real-World Outcomes in Patients with Metastatic Renal Cell Carcinoma from the Molecular-Targeted Therapy Era to the Immune Checkpoint Inhibitor Era.

Hiroki Ishihara et al.PubMed ↗Publisher ↗

No numbers read from the abstract.